← Back to Search

Procedure

Ablative Therapy for Lung Cancer (OBLITERATE Trial)

N/A

Recruiting

Led By Megan Daly, MD

Research Sponsored by University of California, Davis

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age ≥18 years at time of consent

Must have one of the following histologically and/or biochemically confirmed genitourinary malignancies: Cohort A: Non-small cell cancer, Cohort B: Small cell cancer

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months from the first day of ablative local therapy

Awards & highlights

OBLITERATE Trial Summary

This trial looks at how well adding a local therapy can improve outcomes for people with an oligo-progressive solid tumor. Outcomes are measured by time to treatment failure.

Who is the study for?

This trial is for adults over 18 with certain lung cancers (non-small or small cell) who've seen benefits from their current cancer treatment but have a few new or worsening spots of cancer. They must be able to undergo local therapies like radiation and continue their systemic therapy with a short break.Check my eligibility

What is being tested?

The study tests if adding local treatments, such as targeted radiation, to ongoing systemic therapy helps control cancer when only a few areas are getting worse. The main goal is to see how long patients can stay on their current treatment without needing to change it due to the cancer progressing.See study design

What are the potential side effects?

While specific side effects aren't listed here, locally ablative therapies like radiation may cause skin irritation, fatigue, mild pain at the treatment site, and sometimes more serious issues depending on the area treated.

OBLITERATE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have a confirmed diagnosis of either non-small cell or small cell genitourinary cancer.

Select...

I have 5 or fewer new or worsening cancer spots.

OBLITERATE Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months from the first day of ablative local therapy

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months from the first day of ablative local therapy

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months from the first day of ablative local therapy for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants with controlled disease

Secondary outcome measures

Median overall survival

Number of participants experiencing grade ≥ 3 adverse events attributable to ablative local therapy

Time to treatment failure

OBLITERATE Trial Design

1Treatment groups

Experimental Treatment

Group I: Ablative local therapyExperimental Treatment1 Intervention

Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor

911 Previous Clinical Trials

4,709,419 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,672 Previous Clinical Trials

40,926,341 Total Patients Enrolled

Megan Daly, MDPrincipal InvestigatorUniversity of California, Davis

5 Previous Clinical Trials

163 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research endeavor currently looking for participants?

"The clinical trial, which was launched on October 5th 2023 according to information provided by clinicaltrials.gov, is actively recruiting participants. An update occurred as recently as the 19th of October this year."

Answered by AI

What is the cumulative enrolment for this research endeavor?

"Affirmative. According to data hosted on clinicaltrials.gov, this research is currently recruiting participants with the trial first appearing on October 5th of 2023 and last being updated 19 days later. The study requires 100 individuals from a single site for enrollment purposes."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)

Megan Daly, MD 2023. "LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06103682.